ro 31-8220 has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
Ro 31-8220: a protein kinase C inhibitor
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Jia, D | 1 |
| Ao, J | 1 |
| Liu, H | 1 |
| Zang, Y | 1 |
| Azam, M | 1 |
| Habib, SL | 1 |
| Li, J | 1 |
| Ruan, X | 1 |
| Jia, H | 1 |
| Wang, X | 1 |
| Li, B | 1 |
1 other study available for ro 31-8220 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Topics: Animals; Cell Cycle Checkpoints; DNA Damage; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HC | 2016 |